^
Association details:
| Biomarker: | ER positive + CDK6 overexpression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.
Published date:
05/25/2023
Excerpt:
...neoadjuvant palbociclib and ET in pre- or post-menopausal women with ER+/HER2- early BC....Interestingly, we observed higher baseline mRNA expression of CDK6 in patients with absence of US response (p = 0.039) or those with no CCCA (p = 0.004)….High pre-treatment mRNA expression of the CDK6 gene was associated with no US response or absence of CCCA in patients treated with neoadjuvant palbociclib and ET.
Secondary therapy:
Hormone Therapy
DOI:
10.1200/JCO.2023.41.16_suppl.522
Trial ID:
